Advertisement
Organisation › Details
Oxford Science Park, The (TOSP)
The Oxford Science Park is majority owned by Magdalen College, Oxford, upholding its research heritage and its strategy to support discovery, innovation and entrepreneurship. Providing an influential science and technology environment, the Park has ambitious plans to create an additional 500,000+ sq. ft. of office and laboratory space over the next 3 years alongside its strategic partner GIC. This additional capacity will support the growth of businesses already based on the Park, providing flexible workspace accommodation, and enabling new companies to enjoy the Park’s exceptional environment and collegiate and collaborative ethos. TOSP is home to 2,700 people and more than 130 businesses. These range from start-ups based in the Magdalen Centre innovation hub to major international companies and include Blue Earth Diagnostics, MiroBio, OrganOx, OxSonics Therapeutics, Oxford Nanopore Technologies, OXGENE, ProImmune, Oxford Science Enterprises, Evox Therapeutics, Exscientia and Intuitive Surgical. The Oxford Science Park is located approximately four miles south-east of Oxford city centre, just off the City’s southern ring road. It has easy access to the M40 and A34, as well as to Heathrow Airport and mainline train services. *
Start | 1991-01-01 start | |
Group | University of Oxford | |
Industry | business park management / science park management | |
Industry 2 | LIFE SCIENCES | |
Person | Maw, Rory (Univ Oxford 202207 CEO of The Oxford Science Park) | |
Person 2 | Macpherson, Ian (Oxford Science Park 201105 Business Development Manager) | |
Region | Oxford, Oxfordshire | |
Country | United Kingdom (GB) | |
City | OX4 4GA Oxford | |
Tel | +44-1865-784000 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Oxford Science Park, The. (7/18/22). "Press Release: The Oxford Science Park Agrees to Sale of Development Site to the Lawrence J. Ellison Institute for Transformative Medicine". Oxford. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for University of Oxford
- [1] CEPI. (8/29/23). "Press Release: CEPI and University of Oxford to Accelerate Vaccine Development against Disease X". Oslo & Oxford....
- [2] Oxford Science Park, The. (7/18/22). "Press Release: The Oxford Science Park Agrees to Sale of Development Site to the Lawrence J. Ellison Institute for Transformative Medicine". Oxford....
- [3] Oxford Science Enterprises plc. (7/11/22). "Press Release: Oxford Science Enterprises Raises £250 Million"....
- [4] Oxford VR Ltd.. (4/7/22). "Press Release: OxfordVR Technology a World First Success in Automating Psychological Therapy Using Virtual Reality (VR)"....
- [5] Exscientia Ltd.. (8/4/21). "Press Release: Exscientia Builds Automated Laboratories in Oxford to Expand Pipeline"....
- [6] AstraZeneca plc. (12/30/20). "Press Release: AstraZeneca’s COVID-19 Vaccine Authorised for Emergency Supply in the UK"....
- [7] Enara Bio Ltd.. (12/9/20). "Press Release: Enara Bio Relocates to The Oxford Science Park’s Newest Facility to Expand R&D Capabilities in the Search for Novel Vancer Immunotherapies". Oxford & London....
- [8] Evotec SE. (9/2/20). "Press Release: Evotec Expands Its Proprietary Patient Database into Liver Disease with Unique Access to QUOD Biobank". Hamburg....
- [9] Halix B.V.. (4/15/20). "Press Release: Halix Enters Collaboration with the University of Oxford for GMP Manufacturing of a COVID-19 Vaccine". Leiden....
- [10] Oxford University Innovation. (1/23/20). "Press Release: Oxford Investment Opportunity Network and Oxford Angel Network Join Forces"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top